This document provides an overview of chronic myeloid leukemia (CML), including its molecular genetics, clinical manifestations, diagnosis, treatment options and outcomes. CML results from a fusion of the BCR and ABL genes, forming the Philadelphia chromosome and BCR-ABL fusion protein. It progresses through chronic, accelerated and blast crisis phases if left untreated. Tyrosine kinase inhibitors are now the standard first-line treatment and can control the disease long-term in chronic phase, while allogeneic stem cell transplant remains the only potential cure. Resistance and disease progression remain challenges.
Learning Objectives:
Introduction
Definition of CML
Philadelphia Chromosome
Normal Granulopoiesis
Pathogenesis of CML
Aetiology
Incidence
Clinical Features
Phases of CML
Lab Diagnosis of CML
Course & Prognosis
Differential Diagnosis
Brief Overview of Treatment
chronic myeloid leukemia, CML, epidemiology, BCR ABL1 gene, philadelphia chromosome, t(9;22), CML incidence, etiology of CML, pathophysiology of CML, phases of CML, treatment of CML, Allogenic stem cell transplant, TKI therapy for CML, Sokal index for CML,
acute leukemia
For More Medicine Free PPT - http://playnever.blogspot.com/
For Health benefits and medicine videos Subscribe youtube channel - https://www.youtube.com/playlist?list=PLKg-H-sMh9G01zEg4YpndngXODW2bq92w
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
More Related Content
Similar to Chronic myeloid leukemia genetics гбйт ягш
Learning Objectives:
Introduction
Definition of CML
Philadelphia Chromosome
Normal Granulopoiesis
Pathogenesis of CML
Aetiology
Incidence
Clinical Features
Phases of CML
Lab Diagnosis of CML
Course & Prognosis
Differential Diagnosis
Brief Overview of Treatment
chronic myeloid leukemia, CML, epidemiology, BCR ABL1 gene, philadelphia chromosome, t(9;22), CML incidence, etiology of CML, pathophysiology of CML, phases of CML, treatment of CML, Allogenic stem cell transplant, TKI therapy for CML, Sokal index for CML,
acute leukemia
For More Medicine Free PPT - http://playnever.blogspot.com/
For Health benefits and medicine videos Subscribe youtube channel - https://www.youtube.com/playlist?list=PLKg-H-sMh9G01zEg4YpndngXODW2bq92w
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
2. Learning Objectives
Myeloproliferative disorders (MPDs)
Molecular genetics of chronic myeloid
leukemia
Clinical manifestations and diagnosis of
chronic myeloid leukemia
Overview of the treatment of chronic myeloid
leukemia
Initial treatment of chronic myeloid leukemia in
chronic phase
3. Explain how to define and identify a relapse
Treatment of CML in chronic phase after
failure of initial therapy
Clinical use of tyrosine kinase inhibitors for
chronic myeloid leukemia
Treatment of CML in accelerated phase and
blast crisis
Prognosis
Learning Objectives
5. Myeloproliferative Disorders
Clonal disorders of hematopoiesis that arise in
hematopoietic stem or early progenitor cell.
Characterized by the dysregulated production of
particular lineage of mature myeloid cells with fairly
normal maturation.
Exhibit a variable tendency to progress to acute
leukemia
Share abnormalities of hemostasis and thrombosis
Overlap between the clinical features
6. Introduction
CML is a clonal myeloproliferative neoplasm
Dysregulated production and uncontrolled proliferation
of mature and maturing granulocyte with fairly normal
differentiation
Fusion of 2 genes: BCR (or chromosome 22) and ABL1
(on chromosome 9), resulting in BCR-ABL1 fusion gene
Final result: Abnormal chromosome 22 called
Philadelphia (Ph) chromosome
Final product: BCR-ABL1 fusion protein, a dysregulated
tyrosine kinase
7. Uncontrolled production of mature and maturing
granulocytes
Predominantly neutrophils, but also basophils and
eosinophils
Triphasic or biphasic clinical course
Chronic phase, accelerated phase, blast crisis
Introduction
8. Phases of CML (before Imatinib)
Chronic phase
Median duration
5–6 years
Accelerated
phase
Median duration
6–9 months
Blast crisis
Median survival
3–6 months
Advanced phases
9. Epidemiology
Annual incidence: 1 to 2 cases per 100,000
15% – 20% of all adult leukemias
Incidence increases significantly with age
– Median age: ~ 55 years
– Prevalence increasing due to current therapy
– Most patients present in CP, 85%
• Majority of CML-related deaths due to progression to AP/BC
– 50% of CML patients are asymptomatic at diagnosis
Risk factors
– Exposure to ionizing radiation, the only known
10. Molecular Genetics of CML
The Philadelphia chromosome was originally detected by
workers in Philadelphia.
The first genetic abnormality to be associated with a
human cancer.
The result of a balanced translocation between
chromosomes 9 and 22.
Derivative chromosome 22 is significantly smaller
Ph chromosome is present in hematopoietic cells from
patients with CML.
Therefore, the Ph chromosome is acquired and NOT
inherited through the germline.
11. Molecular Genetics of CML
The development of chronic phase CML appears to be a
direct result of the BCR-ABL1 activity, which promotes
its development by allowing:
I. Uncontrolled proliferation of transformed cells
II. Discordant maturation
III. Escape from apoptosis
IV. Altered interaction with the cellular Matrix
The progression of CML from chronic phase to accelerated face or
blast crisis is a complex, multistep process (may be related to GMP).
Also, it appears to involve the constitutive expression of the BCR-
ABL1 tyrosine kinase.
15. Clinical Manifestations
Asymptomatic in 20-50% of patients
Fatigue 34%, weight loss 20%, excessive sweating
15%, abdominal fullness 15%, bleeding episodes
21% (platelet dysfunction).
Abdominal pain in the LUQ (enlarged spleen)
Tenderness over the lower sternum.
Acute gouty arthritis
Findings: Splenomegaly, anemia, WBC > 100,000,
platelet count > 600,000
16. Peripheral Blood Pathology
Leukocytosis (median of 100,000)
Differentiation shows virtually all cells of neutrophilic
series
Blasts < 2%
Myelocytes more than metamyelocytes (a classic finding
in CML)
Neutrophils cytochemistry is abnormal – low LAP score
Basophilia in 90% of cases
Thrombocytosis. If low platelets – consider an other
20. Bone Marrow Pathology
Granulocytic maturation pattern same as in the
peripheral blood
Increased reticulin fibrosis and vascularity
Erythroid islands are reduced in number and size
Dwarf megakaryocytes
Pseudo-Gaucher’s cells and Sea Blue histiocytes
(markers of increased cell turnover)
Iron-laden macrophages are reduced or absent
25. Diagnosis of CML
Typical findings in the blood and bone marrow
Requires the detection of the Ph chromosomal or its
product, the BCR-ABL1 fusion mRNA and the BCR-ABL1
protein.
Conventional cytogenetic analysis (karyotyping) – The first
method
Florence and in situ hybridization (FISH) analysis
RT-PCR (The BEST)
Southern blot techniques – rarely used
Western Blotting – low sensitivity and labor intensive
27. RT-PCR for BCR-ABL
Qualitative RT-PCR allow for
the diagnosis of CML
Quantitative RT-PCR is used
to quantify the amount of
disease
Allows for the identification
of cryptic BCR-ABL
translocations
Does not require a bone
marrow aspirate for optimal
results
Cycle 1
yields 2
molecules
Cycle 2
yields 4
molecules
Cycle 3 yields
8 molecules;
2 molecules
(in white
boxes)
match target
sequence
Denaturation:
Heat briefly to
separate DNA
strands
Annealing: Cool
to allow primers
to form hydrogen
bond with ends
of target
sequence
2
1
Extension: DNA
polymerase adds
nucleotides to the
3” end of each
primer
3
New
nucleo-
tides
Primers
Target
sequence
28. Most CML patients are diagnosed
in the chronic phase
Chronic phase Blastic phase
30. Accelerated Phase CML
10-19% blasts in the peripheral blood or bone
marrow
Peripheral blood basophils ≥20%
Platelets < 100,000/microL, unrelated to therapy
Platelets > 1,000,000/microL, unresponsive to
therapy
Progressive splenomegaly and increasing WBC,
unresponsive to therapy
Cytogenic evolution
31. Blastic Phase CML
Blasts in the peripheral blood ≥20% or in the bone
marrow ≥30%
Large foci or clusters of blasts on the bone marrow
biopsy
Presence of extramedullary blastic infiltrate (e.g.,
myeloid sarcoma, also known as granulocytic
sarcoma or chloroma)
Blast crisis is generally refractory to treatment, occurs
approximately 3-5 years after the diagnosis of CML and
18 months after the onset of accelerated face
35. Principles of CML treatment
Relieve symptoms of hyperleukocytosis,
splenomegaly and thrombocytosis.
Hydration
Chemotherapy (Busulfan, hydroxyurea)
Control and prolonging the chronic phase (non-
curative)
Tyrosine kinase inhibitors
Alpha-interferon + chemotherapy
Chemotherapy (hydroxyurea)
36. Treatment Options
Potential cure with allogeneic
hematopoietic stem cell transplantation
Disease control without cure using
tyrosine kinase inhibitors (TKIs)
Palliative therapy with cytotoxic agents
Treatment decisions for patients with CML are complex,
due to the variety of available options, many of which are
conflicting.
37. Factors influencing choice of
therapy
Phase of CML
Availability of a donor for allogeneic stem cell
transplant
Patient age
Presence of medical co-morbidities
Response to treatment with TKIs
38. IRIS Study Design: Imatinib Mesylate
Versus IFN- + ara-C
S
Imatinib Mesylate
IFN- + ara-C
R Crossover
IF:
Loss of MCR or CHR
Increasing WBC count
Intolerance of treatment
Failure to achieve MCR at 12 months*
Failure to achieve CHR at 12 months*
Request to discontinue IFN-*
Progression
Increasing WBC count
Loss of MCR or CHR
Accelerated phase or blast crisis
Death
S = screening.
R = randomization.
1106 patients enrolled from June 2000 to January 2001
42. Resistance to Imatinib occurs predominantly
during advanced phase CML
Advanced stage cancers
are characterized by
multiple genetic changes
Patients in advanced
phase often relapse with
the development of
chemotherapy resistance
Some patients in blast
crisis CML respond to
Imatinib but then tends
to relapse
Chronic
Phase
Blast
Crisis Relapse
Ph+
Ph+ blasts
Ph-negative
Ph+ Imatinib mesylate-
resistant blasts
Hematopoietic
differentiation
Bone
marrow
to
peripheral
blood
43. Initial Treatment
Imatinib (Gleevec)
Dasatinib (Sprycel)
Nilotinib (Tasigna)
Tyrosine kinase inhibitors are for first-line therapy in
chronic phase CML
1. All 3 agents are considered to be (category 1) based on the NCCN
guidelines and recommendations.
2. Second-generation TKIs (dasatinib or nilotinib) produce faster and
deeper response than imatinib
44. Treatment of CML after failure of
initial therapy
No randomized trials have directly compared the efficacy of
second-generation TKIs in patients with chronic phase CML who
experience failure of an initial TKIs
A trial of another TKI.
Dasatinib preferred in patients with pancreatitis,
elevated bilirubin or hyperglycemia
Dasatinib crosses the blood brain barrier and would
therefore be preferred in patients with CNS involvement
Nilotinib might be chosen for patients with a history of
pleural or pericardial effusion or disease
Dasatinib and Nilotinib can result in QT prolongation
45. Other Options
Bosutinib – toxicity is a limiting factor
Ponatinib – toxicity is a limiting factor
Increase the dose of Imatinib
Omacetaxine mepesuccinate – SQ Injection
Approved by the FDA for patients resistant or
intolerant to 2 or more TKIs
Hematopoietic cell transplant – the only cure
Clinical trials
46. Other Options
Interferon alfa plus cytarabine
Hydroxyurea
Busulfan
Patients who are ineligible for HCT but have either a
contraindication to a second-generation TKI or have failed to
respond to treatment with available TKI
48. Resistance to treatment
Primary resistance – patient fails to
achieve a desired response to initial
treatment
Secondary resistance – patient with an
initial response to a TKI ultimately
relapses
49. Loss of Response
Patients should be re-evaluated with a bone marrow biopsy
with cytogenetics, and BCR-ABL kinase mutation analysis
T315I mutation
Resistant to all TKIs, except Ponatinib
Patient should be evaluated for SCT
Y253H, E255k/V and F359V/C/I mutations
Resistant to Imatinib and Nilotinib but sensitive to Dasatinib
F317L/V/I/C, V299L and T315A mutations
Sensitive to Nilotinib but with intermediate sensitivity to
Imatinib and Dasatinib
50. Mechanisms of action TKIs
They block the initiation of bcr-abl pathway
Many TKIs also affect other signaling pathways
Dasatinib and Bosutinib inhibit both Bcr-Abl and Src
kinases.
Nilotinib inhibits Bcr-Abl, c-kit and platelet derived
growth factor receptor (PDGFR)
These differences in targeted pathways may be
responsible for their varied clinical effects in tumors
51. Mechanisms of Action, Imatinib
Competitively inhibits the inactive configuration of
the Bcr-Abl protein tyrosine kinase
Blocking the ATP binding site and thereby
preventing a conformational switch to the active
form
Inhibits cellular proliferation and tumor formation
Produces 95% decrease in CML colony growth
Inhibits platelet-derived growth factor and c-kit
53. GLEEVEC (Imatinib)
Molecular consequence
of the t(9;22) is the fusion
protein BCR–ABL, which
has increased in tyrosine
kinase activity
BCR-ABL protein
transform hematopoietic
cells so that their growth
and survival become
independent of cytokines
It protects hematopoietic
cells from programmed
cell death (apoptosis)
55. Drug Interaction with TKIs
They are metabolized by the CYP3A4 system – can
inhibit other cytochrome P450 pathways
Therefore, they compete with Coumadin
Low TKIs levels – St. John’s wort, rifampin,
carbamazepine, phenobarbital and phenytoin
High TKIs levels – diltiazem, verapamil, itraconazole,
ketoconazole, clarithromycin, erythromycin and
grapefruit juice
56. Side Effects of TKIs
Imatinib - Bone marrow suppression; fluid retention/edema;
gastrointestinal effects; heart failure; hepatotoxicity
Dasatinib - Bone marrow suppression; pleural/pericardial
effusions; pulmonary arterial hypertension; QT prolongation;
aspirin like effect
Bosutinib - Bone marrow suppression; fluid retention/edema;
gastrointestinal effects
57. Side Effects of TKIs
Nilotinib - Bone marrow suppression;
atherosclerosis-related events; electrolyte
imbalance; hepatotoxicity
Black box: QT prolongation (screening required)
Ponatinib - Bone marrow suppression; fluid
retention/edema; gastrointestinal effects; heart
failure; hypertension; pancreatitis; aspirin-like effect
Black box: Arterial thrombosis; hepatic toxicity
58. Pregnancy and TKIs
All TKIs could be teratogenic during pregnancy
Women are advised not to become pregnant
while on TKIs (any TKI)
Best effective contraception is the barrier
Woman taking TKIs are advised to avoid to
breast-feeding
59. Prognosis
Improved dramatically since the incorporation of
tyrosine kinase inhibitors into the initial treatment
SEER database. 5138 patient’s, year 2000 and 2005
15-44 years – OS 72 versus 86%
45-64 years – OS 68 versus 76%
65-74 years – OS 38 versus 51%
75-84 years – OS 19 versus 36%
Stage of disease at the time of diagnosis is the
strongest single predictor of outcome.